NDA 050297 · Azurity
E.E.S.
Erythromycin Ethylsuccinate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 15, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1970
Aug 6, 1970
Approved uses
1
Original approval plus efficacy supplements
Registered trials
897
218 Phase 3, 47 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 6, 1970 Original approval
2 products under this application
- E.E.S. · ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE · TABLET, CHEWABLE, ORAL · Discontinued
- ERYPED · ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE · TABLET, CHEWABLE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Erythromycin Ethylsuccinate" as an intervention, any sponsor and status, largest first.
- Azithromycin for Child Survival in Niger IIPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06358872 · 3,300,000 participants (planned) · Start Apr 29, 2024 · Primary completion Apr 29, 2028
Drug: Azithromycin for Oral Suspension · For: Mortality; Antimicrobial Resistance
Sites: Niamey, Niger
- Azithromycin for Child Survival in Niger: Mortality and Resistance TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04224987 · 864,493 participants · Start Nov 24, 2020 · Primary completion Jul 31, 2024
Drug: Azithromycin · For: Mortality; Resistance Bacterial; Child, Only
Sites: Niamey, Niger
FHI 360Academic, hospital or other
NCT05016895 · 767,535 participants · Start Aug 27, 2021 · Primary completion Jun 30, 2024
Drug: Single-dose azithromycin · For: Child Mortality
Sites: Abidjan, Côte d’Ivoire
- Infant Mortality Reduction by the Mass Administration of AzithromycinPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT04716712 · 694,400 participants (planned) · Start Oct 4, 2021 · Primary completion Jan 30, 2025
Drug: Azithromycin; Placebo · For: Child Mortality
Sites: San Francisco, California; Nouna, Burkina Faso; Ouagadougou, Burkina Faso
- Kebele Elimination of Trachoma for Ocular HealthPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT03335072 · 320,000 participants (planned) · Start Feb 7, 2022 · Primary completion Mar 1, 2027
Drug: Azithromycin · For: Trachoma
Sites: San Francisco, California; Bahir Dar, Ethiopia
- Mortality Reduction After Oral Azithromycin: Mortality StudyPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02047981 · 190,238 participants · Start Dec 2014 · Primary completion Sep 2018
Drug: Azithromycin; Placebo · For: Childhood Mortality
Sites: San Francisco, California; Baltimore, Maryland; Blantyre, Malawi · 6 sites in all
- Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)Pivotal-lookingTerminated
University of California, San FranciscoAcademic, hospital or other
NCT05288023 · 169,707 participants · Start Dec 1, 2022 · Primary completion Jan 15, 2024
Drug: Azithromycin for Oral Suspension · For: Resistance Bacterial; Morality; Child Health and 1 more
Sites: San Francisco, California
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in MaliPivotal-lookingCompleted
Tampere UniversityAcademic, hospital or other
NCT04424511 · 149,201 participants · Start Oct 15, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Azithromycin · For: Mortality
Sites: Bamako, Mali
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis.
Hoppe JE, Halm U, Hagedorn HJ, et al. · Infection 1989 · Clinical Trial, Comparative Study
- Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses.
Yakatan GJ, Rasmussen CE, Feis PJ, et al. · J Clin Pharmacol 1985 · Clinical Trial, Comparative Study
- Antibiotics for whooping cough (pertussis).
Altunaiji S, Kukuruzovic R, Curtis N, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Relative bioavailability of enteric coated pellets, stearate and ethylsuccinate formulations of erythromycin.
Tjandramaga TB, Van Hecken A, Mullie A, et al. · Pharmacology 1984 · Clinical Trial, Comparative Study
- Effects of morning versus evening combined strength and endurance training on physical performance, muscle hypertrophy, and serum hormone concentrations.
Küüsmaa M, Schumann M, Sedliak M, et al. · Appl Physiol Nutr Metab 2016 · Comparative Study, Randomized Controlled Trial
- Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview.
Gentry LO · J Antimicrob Chemother 1987 · Clinical Trial, Randomized Controlled Trial
Sponsor: Azurity · Also marketed as Eryped
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.